Home > Oncology > ESMO 2021 > Melanoma > Durable intracranial responses with nivolumab/ipilimumab

Durable intracranial responses with nivolumab/ipilimumab

Presented By
Dr Kim Margolin, City of Hope, CA, USA
Conference
ESMO 2021
Trial
Phase 2, CheckMate204
Melanoma patients with brain metastases can have a durable intracranial response with first-line nivolumab/ipilimumab, long-term results of CheckMate204 showed. Brain metastases are a common complication of solid tumours and remain a major cause of disabling neurologic complications and death in patients with cancer. Surgical resection and stereotactic radiotherapy are highly effective treatments for local control. However, these treatments do not have any effect on the risk of the development of new brain metastases, on the control of extracranial disease, or on overall survival (OS). The open-label, phase 2 CheckMate204 trial (NCT02320058) evaluated efficacy and safety of nivolumab/ipilimumab as treatment in melanoma patients with brain metastases. Previous results showed clinically meaningful intracranial efficacy, concordant with extracranial activity, ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on